Hellmann, Matthew

Publications

Sort by

Co-Author Network

selected publications

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 46
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 27
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 26
TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019 Academic Article GET IT
Times cited: 124
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 34
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Review GET IT
Times cited: 24
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 13
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 30
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 45
Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019 Academic Article GET IT
Times cited: 141
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. The Lancet. Respiratory medicine. 2019 Academic Article GET IT
Times cited: 43
Adding to the checkpoint blockade armamentarium. Nature medicine. 2019 Comment GET IT
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer research. 2018 Academic Article GET IT
Times cited: 47
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 2
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 418
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 257
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 66
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 90
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal for immunotherapy of cancer. 2018 Academic Article GET IT
Times cited: 60
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 90
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 204
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 124
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 441
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 304
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 82
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 422
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 941
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, N.Y.). 2018 Academic Article GET IT
Times cited: 300
PD-1/PD-L1 Axis in Lung Cancer. Cancer journal (Sudbury, Mass.). 2018 Review GET IT
Times cited: 20
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017 Academic Article GET IT
Times cited: 214
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 74
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PloS one. 2017 Academic Article GET IT
Times cited: 17
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature communications. 2017 Academic Article GET IT
Times cited: 71
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS medicine. 2017 Academic Article GET IT
Times cited: 102
Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017 Academic Article GET IT
Times cited: 219
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 960
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer immunology research. 2017 Academic Article GET IT
Times cited: 137
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 115
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 17
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 185
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 216
Reply to M. Nishino et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Letter GET IT
Times cited: 1
'Genotype/immunotype' correlations in resected NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 30
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 44
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 490
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 393
Chemotherapy remains an essential element of personalized care for persons with lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Review GET IT
Times cited: 35
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Conference Paper GET IT
Times cited: 274
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 255
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 65
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 45
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European journal of cancer. 2016 Academic Article GET IT
Times cited: 169
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 160
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 1237
Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails". JAMA oncology. 2016 Article GET IT
Times cited: 29
Combinatorial Cancer Immunotherapies. 2016 GET IT
Times cited: 50
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 19
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 41
Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Molecular & cellular oncology. 2015 Academic Article GET IT
Times cited: 27
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 771
Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. Clinical lung cancer. 2015 Academic Article GET IT
Times cited: 13
Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 3166
Genetics and immunology: reinvigorated. Oncoimmunology. 2015 Academic Article GET IT
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Cancer. 2015 Academic Article GET IT
Times cited: 9
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 3825
Left ventricular false tendons: echocardiographic characteristics in the Polish population. Folia morphologica. 2015 Academic Article GET IT
Times cited: 1
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 67
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 21
Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer. 2014 Academic Article GET IT
Times cited: 61
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 127
Chemotherapy for lung cancers: here to stay. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 5
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 8

more ...

less ...

Background

education and training

M.D., The Johns Hopkins University School of Medicine 2008
B.A., University of Pennsylvania 2004

Contact

full name

Matthew Hellmann

VIVO Weill Cornell Medical College

Matthew Hellmann Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name